RCL
76
3
SPG
50
4
BLK
54
4
FDX
36
3
MAC
54
3
KMX
58
6
HAL
34
7
SRE
47
7
UPS
53
3
ADSK
63
2
COF
52
5
HCA
39
2
MCHP
37
3
GOOGL
66
2
JBHT
48
2
MAT
43
2
TROW
48
6
PNR
60
3
PSX
27
2
FOX
73
3
RCL
76
3
SPG
50
4
BLK
54
4
FDX
36
3
MAC
54
3
KMX
58
6
HAL
34
7
SRE
47
7
UPS
53
3
ADSK
63
2
COF
52
5
HCA
39
2
MCHP
37
3
GOOGL
66
2
JBHT
48
2
MAT
43
2
TROW
48
6
PNR
60
3
PSX
27
2
FOX
73
3
Financhill
Back

Phathom Pharmaceuticals 10K Form

Sell
18

PHAT
Phathom Pharmaceuticals

Last Price:
$7.75
Seasonality Move:
-9.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PHAT News And Ratings

See the #1 stock for the next 7 days that we like better than PHAT

PHAT Financial Statistics

Sales & Book Value

Annual Sales: $682K
Cash Flow: $-63.6M
Price / Cash Flow: 0
Annual Sales: $-2.74
Price / Book: 0

Profitability

EPS (TTM): -5.75000
Net Income (TTM): $-339.4M
Gross Margin: $515K
Return on Equity: 0%
Return on Assets: -91.94%

Phathom Pharmaceuticals Earnings Forecast

Key Phathom Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 2 years for PHAT is 75.51%.
  • The Selling, General & Administrative Expenses for PHAT have been equal to 17,291.50% of Gross Profit Margin.
  • The Research & Development expenses have been 7,316.57% of Revenue.
  • The Interest Expense is -20.82% of Operating Income.
  • The Net Earning history of PHAT is -29,558.94% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Phathom Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PHAT
CUSIP: 71722W
Website: phathompharma.com

Debt

Debt-to-Equity Ratio: -0.94
Current Ratio: 5.73
Quick Ratio: 5.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PHAT Technical Analysis vs Fundamental Analysis

Sell
18
Phathom Pharmaceuticals (PHAT) is a Sell

Is Phathom Pharmaceuticals a Buy or a Sell?